News
Return of FDA official targeted by Trump allies hits biotech shares
Sarepta shares dropped as much as 5.2 per cent on Monday amid volatile trading, while those of Replimune — another gene therapy group — fell as much as 15.1 per cent. Replimune has a drug pending approval before the FDA division Prasad oversees. The declines eroded some of the gains the stocks experienced following his departure.
Vinay Prasad is once again head of the FDA’s Center for Biologics Evaluation and Research, after Laura Loomer led a campaign ...
A Food and Drug Administration official who stepped down less than two weeks ago is getting his job back as the agency’s top ...
Loomer is an influential figure in right-wing circles. She was present alongside Trump on the 2024 campaign trail, and she ...
Vinay Prasad, the U.S. Food and Drug Administration's top vaccine regulator, is returning to his post less than two weeks ...
Some people in the bud biz are cautiously optimistic about cannabis reform, but others think he's “pandering to people on an ...
Plus more pharma news from the Pharmalittle newsletter.
The Food and Drug Administration has rehired the vaccine chief who resigned just two weeks ago. Dr. Vinay Prasad led the ...
Vinay Prasad, a professor who until earlier this year headed a cancer-drugs and health-policy lab at UC San Francisco, ...
Vinay Prasad’s ouster as the Food and Drug Administration’s top vaccine and gene therapy regulator came after frustration ...
The U.S. Food and Drug Administration on Thursday announced a new program to speed up construction and review of drug ...
The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere to ...
In an interview taped before Trump announced his Friday summit with Russian President Vladimir Putin over Russia’s war with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback